Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Phase I, Open Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies.

NCT05024305 is registered in ClinicalTrials.gov with Shandong TheraWisdom Biopharma Co., Ltd. as lead sponsor.

NCT NCT05024305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05024305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Phase I, Open Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies.
Lead sponsor
Shandong TheraWisdom Biopharma Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
March 8, 2022
Completion date
June 30, 2023
Enrollment
81 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies